alexa Medical Journals In Personalised Biomarker|Omics Group|Journal Of Molecular Biomarkers And Diagnosis

OMICS International organises 3000+ Global Conferenceseries Events every year across USA, Europe & Asia with support from 1000 more scientific societies and Publishes 700+ Open Access Journals which contains over 50000 eminent personalities, reputed scientists as editorial board members.

Medical Journals In Personalised Biomarker

Although chemotherapy is commonly used in cancer treatment, it is only 25% effective. The p53 tumor suppressor is crucial for both cancer development and response to therapy, but has been less amenable to therapeutic applications due to the complexity of its action reflected in 68,000 papers describing its function. Here we provide a systematic approach to integrate this vast amount of information by constructing a large-scale logical model of the p53 interactome from database and literature information. The model contains 206 nodes representing genes or proteins, DNA damage input, apoptosis and cellular senescence outputs, connected by 738 logical interactions. Predictions from model analysis including in silico knock-outs and steady state analysis were validated using literature searches and in vitro based experiments. Novel findings included upregulation of Chk1, ATM and ATR pathways in p53 negative cells and numerous changes in pathways brought on by knock-out tests mimicking mutations. The comparison of model simulations with microarray data demonstrated a significant rate of successful predictions ranging between 52% and 71% depending on the cancer type. Growth factors and receptors were identified as biomarkers contributing selectively to the control of osteosarcoma and colon cancer cell growth. In summary, we show that a systematic compilation of knowledge into dynamic models provides predictive value and better understanding of p53 actions. This approach will facilitate identification of individual patients' biomarkers and treatment, will define a sub population of 'high' responders for design and management of clinical trials, and identify shifts in signaling pathways that give rise to resistance to therapy. (MarijaKrstic-Demonacos: New approaches to personalised biomarker identification)
 
  • Share this page
  • Facebook
  • Twitter
  • LinkedIn
  • Google+
  • Pinterest
  • Blogger
 
adwords